Prof Ranjit Manchanda is a professor at the Wolfson Institute of Population Health (WIPH), Queen Mary University of London and leads the Women’s Precision Prevention Team. He is co-Lead for the Cancer Screening, Prevention and Epidemiology Unit at the Centre for Cancer Screening, Prevention & Early Diagnosis in WIPH. He is a Consultant Gynaecological Oncologist at Barts Health NHS Trust, London, and leads their Women’s Precision Prevention Service. He holds an Honorary Professorship at the Department of Health Services Research, London School of Hygiene & Tropical Medicine.

Prof Manchanda's main research interests are focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and precision medicine approaches for risk prediction, stratification, targeted screening and targeted cancer prevention, along with health economic issues related to these areas of research. He is the Chief Investigator on the PROTECTOR, PROTECT-C, DETECT-2, PRESCORES, SECRETS, JHCR, UKCOGS, SIGNPOST, PROMISE Pilot RRESDO and GCaPPS trials/studies.

Prof Manchanda has published and lectured widely on areas of research interest. He is a member of a number of advisory and oversight committees. He is the Topic Advisor (Clinical Lead) for the NICE guideline on Ovarian cancer: identifying and managing familial and genetic risk. He Chairs the UK National Cancer Research Institute (NCRI) Gynaecological Cancer Early Diagnosis Working Group. He is the Specialty Research Lead for Gynaecological Cancer, NIHR North Thames Clinical Research Network (CRN). He is an NHS Innovation Accelerator Alumnus and has served as the President of European Network of Young Gynaecological Oncologists.